SCHEMBL5510014

SCHEMBL5510014

O=S(O)CC(F)CNC1CCc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.47
MAOB P27338 4/20 0.47
BCHE P06276 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
ACHE P22303 1/20 0.47
ADRA1A P35348 1/20 0.47
HTR6 P50406 1/20 0.47
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 5/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5507434 0.82 MAOA (0.47) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL6009426 0.80 GRIN2B (0.53) MAOAMAOBKDM4EKMT2ALMNA
SCHEMBL5503266 0.80 MAOA (0.56) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL5502101 0.74 MAOA (0.47) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL23330224 0.74 MAOA (0.64) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL5503234 0.72 MAOA (0.47) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL9499569 0.71 MAOA (0.63) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL8041215 0.71 MAOA (0.55) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL1974432 0.71 MAOA (0.55) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL1971825 0.71 MAOA (0.55) MAOAMAOBBCHEADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828111-A2 METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2007-09-05 EP disclosed
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed
WO-2006059252-A2 METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR MAOA 63/4885MAOB 65/4885BCHE 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.